acamprosate sold brand name campral medication used along counseling treat alcohol use acamprosate thought stabilize chemical signaling brain would otherwise disrupted alcohol used alone acamprosate effective therapy alcohol use disorder studies found acamprosate works best used combination psychosocial support since drug facilitates reduction alcohol consumption well full serious side effects include allergic reactions abnormal heart rhythms low high blood pressure less serious side effects include headaches insomnia diarrhea common unclear use safe world health organizations list essential acamprosate useful used along counseling treatment alcohol use three twelve months increases number people drink number days without appears work well naltrexone maintenance abstinence however naltrexone works slightly better reducing alcohol cravings heavy acamprosate tends work poorly outside europe treatment services less acamprosate primarily removed kidneys dose reduction suggested moderately impaired kidneys creatinine clearance mlmin also contraindicated strong allergic reaction acamprosate calcium us label carries warnings increases suicidal behavior major depressive disorder kidney adverse effects caused people stop taking drug clinical trials included diarrhea nausea depression potential adverse effects include headache stomach pain back pain muscle pain joint pain chest pain infections flulike symptoms chills heart palpitations high blood pressure fainting vomiting upset stomach constipation increased appetite weight gain edema sleepiness decreased sex drive impotence forgetfulness abnormal thinking abnormal vision distorted sense taste tremors runny nose coughing difficulty breathing sore throat bronchitis pharmacodynamics acamprosate complex fully however believed act nmda receptor antagonist positive allosteric modulator gabaa activity receptors indirect unlike agents used inhibition gabab system believed cause indirect enhancement gabaa effects nmda complex dosedependent product appears enhance receptor activation low concentrations inhibiting consumed higher amounts counters excessive activation nmda receptors context alcohol product also increases endogenous production ethanol benzodiazepines act central nervous system binding gabaa receptor increasing effects inhibitory neurotransmitter gaba ie act positive allosteric modulators alcohol use disorder one main mechanisms tolerance attributed gabaa receptors becoming downregulated ie receptors become less sensitive alcohol longer consumed downregulated gabaa receptor complexes insensitive gaba typical amount gaba produced little effect leading physical withdrawal since gaba normally inhibits neural firing gabaa receptor desensitization results unopposed excitatory neurotransmission ie fewer inhibitory postsynaptic potentials occur gabaa receptors leading neuronal overexcitation ie action potentials postsynaptic neuron one acamprosates mechanisms action enhancement gaba signaling gabaa receptors via positive allosteric receptor purported open chloride ion channel novel way require gaba cofactor making less liable dependence benzodiazepines acamprosate successfully used control tinnitus hyperacusis ear pain inner ear pressure alcohol use due spasms tensor tympani musclemedical citation needed addition alcohol also inhibits activity nmethyldaspartate receptors chronic alcohol consumption leads overproduction upregulation receptors thereafter sudden alcohol abstinence causes excessive numbers nmdars active normal contribute symptoms delirium tremens excitotoxic neuronal withdrawal alcohol induces surge release excitatory neurotransmitters like glutamate activates acamprosate reduces glutamate drug also protects cultured cells excitotoxicity induced ethanol glutamate exposure combined ethanol substance also helps reestablish standard sleep architecture normalizing stage rem sleep phases believed important aspect pharmacological acamprosate metabolized human acamprosates absolute bioavailability oral administration approximately bioavailability decreased taken following administration absorption acamprosate excreted unchanged ie acamprosate via absorption elimination slow tmax hours elimination half life acamprosate developed lipha subsidiary merck approved marketing europe needed october forest laboratories acquired rights market drug approved fda july first generic versions acamprosate launched us acamprosate development confluence pharmaceuticals potential treatment fragile x syndrome drug granted orphan status use fda ema acamprosate inn ban substance acamprosate calcium usan jan also technically known nacetylhomotaurine calcium acetylhomotaurinate sold brand name addition apparent ability help patients refrain drinking evidence suggests acamprosate neuroprotective protects neurons damage death caused effects alcohol withdrawal possibly causes httpsenwikipediaorgwikiacamprosate